Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The decline in upfront contractual payment income associated with the out-licensing of KRP-M223, drug price revisions, growth in new drugs, higher sales of generic pharmaceuticals, and higher research and development expenses due to upfront payments related to KRP-A225 and KRP-126.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥126,257 million (YoY -2.9%) |
| Operating profit | ¥3,567 million (YoY -71.6%) |
| Ordinary income | ¥4,031 million (YoY -69.5%) |
| Profit attributable to owners of the parent | ¥3,448 million (YoY -62.0%) |
| Net income per share | ¥60.03 |
| Operating Margin | 2.8％ |
| Equity ratio | End of the current fiscal period 72.9％ / End of previous period 70.4％ |
| Total assets | ¥195,455 million |
| Net assets | ¥142,425 million |
| Cash flows from operating activities | ¥6,381 million |
| Cash flows from investing activities | ¥-1,644 million |
| Cash flows from financing activities | ¥-7,956 million |
| Cash and cash equivalents at end of period | ¥11,802 million |
| Full-year earnings forecast | Net Sales ¥121,800 million (YoY -3.5%) / Operating profit ¥2,000 million (YoY -43.9%) / Ordinary income ¥2,300 million (YoY -42.9%) / Net income ¥1,500 million (YoY -56.5%) |
| Annual Dividend Forecast | ¥57 → ¥25（-56.1%） |
| Payout ratio | 96.9％ |
| Depreciation and amortization | ¥4,663 million |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥5 million, Item Gain on sale of investment securities / Amount ¥368 million, Item Subsidy Income / Amount ¥100 million / Extraordinary loss Item Loss on disposal and sale of non-current assets / Amount ¥53 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | On 24 April 2026, the company entered into a basic agreement to transfer its generic pharmaceuticals business to 株式会社医薬品共創機構 (provisional), which is expected to be jointly funded by Daito Pharmaceutical Co.,Ltd. and other companies. The final agreement is scheduled to be signed by the end of September 2026, and the transfer is scheduled to take effect on 1 April 2027. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts, institutional investors and others) |
| Issued Shares at Period-End | 59,945,641 |
| Treasury Shares at Period-End | 2,499,346 |
| Factors Behind Changes in Business Performance | The decline in upfront contractual payment income associated with the out-licensing of KRP-M223, drug price revisions, growth in new drugs, higher sales of generic pharmaceuticals, and higher research and development expenses due to upfront payments related to KRP-A225 and KRP-126. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited a decline in upfront contractual payment income associated with the out-licensing of KRP-M223, which had been recorded in the previous fiscal year, the impact of drug price revisions, and higher research and development expenses due to upfront payments related to KRP-A225 and KRP-126. For the next fiscal year, the company expects the impact of drug price revisions and lower revenue, while forecasting lower selling, general and administrative expenses from cost reductions and the absence of the upfront payment income recorded in the current fiscal year.